Ms. Shanthi Kalathil, Mr. Taylor Boas
{
"authors": [
"Shanthi Kalathil"
],
"type": "legacyinthemedia",
"centerAffiliationAll": "",
"centers": [
"Carnegie Endowment for International Peace"
],
"collections": [],
"englishNewsletterAll": "",
"nonEnglishNewsletterAll": "",
"primaryCenter": "Carnegie Endowment for International Peace",
"programAffiliation": "",
"programs": [],
"projects": [],
"regions": [
"China"
],
"topics": []
}REQUIRED IMAGE
China's Stockmarket Has a Case of the Shakes
Source: Carnegie
About the Author
Former Associate
- Internet and State Control in Authoritarian Regimes: China, Cuba, and the CounterrevolutionPaper
Recent Work
Carnegie does not take institutional positions on public policy issues; the views represented herein are those of the author(s) and do not necessarily reflect the views of Carnegie, its staff, or its trustees.
More Work from Carnegie Endowment for International Peace
- As It Turns 25, the Shanghai Cooperation Organization Reflects the New World OrderCommentary
With the growth in points of friction between the great powers, organizations like the SCO will continue to play a role in the strategic adaptation of the smaller powers caught between them.
Temur Umarov
- The Two Key Takeaways From Xi’s Egypt VisitCommentary
Amid celebrations of bilateral ties was a deeper focus on stability in the Middle East.
Amr Hamzawy
- Is the Shanghai Cooperation Organisation Performance Art or Meaningful Collaboration?Commentary
Xi, Putin, and other regional leaders are back-slapping in Bishkek, but the SCO has yet to answer the most serious questions about continental Asia's economic future.
Evan A. Feigenbaum
- Who Paid for China’s Last Debt Cleanup, and Who Will Pay for the Next?Commentary
China’s banking crisis in the 2000s was resolved by transferring the costs to households through financial repression—a decision that recapitalized the banks while exacerbating the structural imbalances that continue to shape the Chinese economy today.
Michael Pettis
- Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. SanctionsCommentary
Chinese biotech companies have been on the receiving end of U.S. economic coercion. Yet their responses have differed significantly because firm and state interests are not uniformly aligned. For Washington, treating all Chinese tech firms the same, irrespective of their actual interests, risks pushing them farther into Beijing’s corner.
Xue Gong